Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A. Lerner
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer
Highlights • Fulvestrant is licensed for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. • One of the largest studied patient cohorts treated with fulvestrant, with data collection from nine UK centres. • Results confirm a modest radiological response rate even in a predominantly pretreated cohort. • Fair access to fulvestrant monotherapy in England should be standard to enable its use in patients most likely to benefit.
Is Universal Patient Access to Fulvestrant in Hormone Receptor-positive Advanced Breast Cancer Justified? A UK Retrospective Multicentre Study
A. Lerner 1 Author Footnotes K. Keshwani 1 Author Footnotes B. Sanderson R.E. Board M. Flynn E. Sharkey A. Okines A. Konstantis R. Roylance R. Roylance Affiliations University College London Hospitals NHS Foundation Trust & NIHR University College London Hospitals Biomedical Research Centre, London, UK Search for articles by this author D. Hanna J. King R. Murphy F. Rehman A. Guppy C. Westbury E. Takeuchi E. Spurrell F.
Clinical Oncology
Erratum for Meletiadis et al., “Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone”
Erratum for Meletiadis et al., “Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone” J. Meletiadis, A. Turlej-Rogacka, A. Lerner, A. Adler, E. Tacconelli, J. W. Mouton the SATURN Diagnostic Study Group Antimicrobial Agents and Chemotherapy Nov 2018, 62 (12) e02184-18; DOI: 10.1128/AAC.02184-18
AUGMENTATION OF THE VIRULENCE OF MURINE COXSACKIE-VIRUS B-3 MYOCARDIOPATHY BY EXERCISE
Abstract Coxsackievirus B-3 myocardiopathy was induced in weanling mice by intraperitoneal and intracerebral inoculations of the Nancy strain. Acute mortality was 5.5%. The cardiomyopathy is characterized by an early phase lasting about 9 days with myocardial necrosis, associated inflammation, and healing by fibrosis and calcification involving 25 to 50% of the contractile fibers in each affected mouse. Infectious coxsackievirus may be recovered from the heart during this phase.
Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset
Antibodies to EBV EA(D) and neutralizing antibodies against the encoded-proteins EBV DNA polymerase and deoxyuridine triphosphate nucleotidohydrolase (dUTPase) were present in the EBV subset CFS patients. Of the sera samples obtained from patients with CFS 93.9% were positive for EA(D), while 31.6% of the control patients were positive for EBV EA(D).
Evaluation of the Efficacy of Fulvestrant in Locally Advanced and Metastatic Breast Cancer in a Single Breast Unit
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Purpose: Access to fulvestrant across the UK has been limited since its removal from the CDF in 2013. Patients treated with fulvestrant have a statistically significant improvement in progression-free survival (PFS) compared with those treated with anastrozole (16.6 m versus 13.8 m, P=0.048) [1].
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack